121 related articles for article (PubMed ID: 22290934)
1. In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography.
te Beek ET; de Boer P; Moerland M; Schmidt ME; Hoetjes NJ; Windhorst AD; van Berckel BN; Cohen AF; van Gerven JM; Lammertsma AA
J Psychopharmacol; 2012 Aug; 26(8):1128-35. PubMed ID: 22290934
[TBL] [Abstract][Full Text] [Related]
2. D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.
Schmidt ME; de Boer P; Andrews R; Neyens M; Rossenu S; William Falteos D; Mannaert E
Psychopharmacology (Berl); 2012 Dec; 224(4):549-57. PubMed ID: 22773165
[TBL] [Abstract][Full Text] [Related]
3. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride.
Kim JH; Son YD; Kim HK; Lee SY; Cho SE; Kim YB; Cho ZH
J Clin Psychopharmacol; 2011 Aug; 31(4):507-11. PubMed ID: 21694619
[TBL] [Abstract][Full Text] [Related]
7. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.
Catafau AM; Suarez M; Bullich S; Llop J; Nucci G; Gunn RN; Brittain C; Laruelle M;
Neuroimage; 2009 Jun; 46(2):447-58. PubMed ID: 19233294
[TBL] [Abstract][Full Text] [Related]
8. The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.
Tolboom N; Berendse HW; Leysen JE; Yaqub M; van Berckel BN; Schuit RC; Ponsen MM; Bakker E; Hoetjes NJ; Windhorst AD; Carlsson ML; Lammertsma AA; Carlsson A
Neuropsychopharmacology; 2015 Jan; 40(2):472-9. PubMed ID: 25248987
[TBL] [Abstract][Full Text] [Related]
9. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography.
Alakurtti K; Johansson JJ; Tuokkola T; Någren K; Rinne JO
Neuroimage; 2013 Nov; 82():252-9. PubMed ID: 23727314
[TBL] [Abstract][Full Text] [Related]
10. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
[TBL] [Abstract][Full Text] [Related]
11. Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography.
Smith GS; Ma Y; Dhawan V; Chaly T; Eidelberg D
Synapse; 2009 Jan; 63(1):1-6. PubMed ID: 18925655
[TBL] [Abstract][Full Text] [Related]
12. Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride.
Hirvonen J; Aalto S; Lumme V; Någren K; Kajander J; Vilkman H; Hagelberg N; Oikonen V; Hietala J
Nucl Med Commun; 2003 Dec; 24(12):1207-14. PubMed ID: 14627846
[TBL] [Abstract][Full Text] [Related]
13. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
[TBL] [Abstract][Full Text] [Related]
15. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.
Takahata K; Ito H; Takano H; Arakawa R; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Nogami T; Suzuki M; Nagashima T; Shimada H; Kato M; Mimura M; Suhara T
Psychopharmacology (Berl); 2012 Jul; 222(1):165-72. PubMed ID: 22237854
[TBL] [Abstract][Full Text] [Related]
16. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.
Nordström AL; Nyberg S; Olsson H; Farde L
Arch Gen Psychiatry; 1998 Mar; 55(3):283-4. PubMed ID: 9510228
[No Abstract] [Full Text] [Related]
18. No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study.
Ito H; Arakawa R; Takahashi H; Takano H; Okumura M; Otsuka T; Ikoma Y; Shidahara M; Suhara T
Int J Neuropsychopharmacol; 2009 Jun; 12(5):667-75. PubMed ID: 18937879
[TBL] [Abstract][Full Text] [Related]
19. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
20. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
